Introduction
Cardiac haemochromatosis is an important and potentially preventable cause of heart failure (HF). However, this condition is often diagnosed in the latter stages of the disease, when complications may have already developed. Iron deposition in the heart often causes arrhythmias and progressive systolic dysfunction. This usually manifests itself in the form of dilated cardiomyopathy with low left ventricular ejection fraction (LVEF), which can be reversible only if it is diagnosed and treated in its early stages. This unique genetic condition is often asymptomatic until the middle age, at which point iron levels finally exceed the storage capacity of cells and tissue is damaged, resulting in cirrhosis, hypogonadism, diabetes, arthropathy, cardiomyopathy, and skin pigmentation. In this case, we discuss the difficulties of differential diagnosis of cardiac haemochromatosis and the effect of specific and HF treatment.
Timeline Case presentation
A 48-year-old-man was referred to the Vilnius University Hospital Santaros Klinikos due to atrial fibrillation with a rapid ventricular response, which was subsequently restored to sinus rhythm by using DC cardioversion. Of note, his electrocardiography ( Figure 1 ) additionally showed decreased voltage in the limb leads and non-specific repolarization abnormalities. He presented with typical symptoms and objective signs of HF, and it was known from medical history that a previous echocardiography (done in 2013) had shown biventricular dilatation and impaired left ventricular (LV) function. Despite complaining of increasing weakness, fatigue, shortness of breath, and abdominal volume, the patient did not take any cardiac medication before index hospitalization. Transthoracic echocardiography confirmed significant ventricular dilatation and systolic dysfunction (LVEF 27%) with severe reduction of global and regional longitudinal strain ( Figure 2 ). Ischaemic origin of HF was excluded during the initial workup by invasive angiography, family history was negative. Past medical history was significant for the following conditions: cirrhosis (Child B class) with hepatosplenomegaly, ascites and portal hypertension, diabetes mellitus with diabetic foot, and chronic kidney disease.
Importantly, a subsequent more careful inspection revealed bronze-shaded skin, telangiectasia on the shoulders and abdomen, and slightly yellowish eyes. These special features combined with concomitant cirrhosis, diabetes, and cardiomyopathy stimulated the testing of iron metabolism markers. Laboratory tests' results consistent with iron overload and their dynamic changes after treatment are presented in the Table 1 .
In order to detect the iron accumulation in the heart cardiac magnetic resonance (CMR) was performed on a 1.5 T scanner (Siemens Avanto, Erlangen, Germany) with measurement of T2* relaxation time of the heart and liver, and LV function, volumes, and mass. The morphometric, functional and T2* relaxation values are presented in Table 2 . The changes in LV systolic function and liver before and after treatment are illustrated in the Supplementary material online, Images S1a-c, S2a and b, S3a-c, and S4a, b. Cardiac magnetic resonance findings were consistent with the diagnosis of myocardial and hepatic siderosis.
Hereditary or Type I haemochromatosis (HHC) was confirmed by a genetic test, showing the potential (>90%) homozygous genotype for the C282Y mutation of the HFE gene.
During 2 weeks of hospitalization specific therapy with deferiprone and standard HF treatment was initiated, regular phlebotomies (removing about 500 mL of blood) were also scheduled. Medical treatment at different timepoints is presented in Table 3 . Dietary advice included restrictions of iron intake (meaning to avoid red meat, crustaceans), as well as vitamin C and alcohol. The chelate, used for about 1 month, was discontinued due to limited availability and high cost in Lithuania. The improvement of iron metabolism markers was interpreted as a good response to regular phlebotomies, therefore, a multidisciplinary team decided to leave therapeutic phlebotomy (every 2 weeks) as a main treatment for haemochromatosis.
Discussion
Cardiac haemochromatosis is the term used to describe the cardiac dysfunction that results from the accumulation of iron in the heart whether from primary or secondary HHC with a varying degree of cardiac involvement. The mutations leading to hereditary HHC are not rare, especially among white populations. In Lithuania, the reported prevalence of C282Y mutation in the haemochromatosis (HFE) gene on chromosome 6 is 2.6% which is similar to the other Central and Eastern European countries with population of Slavic origin. 1 Not all patients that are homozygous for C282Y or compound heterozygous (C282Y/H63D) develop iron overload. 2 The factors affecting penetrance are sex, age, physiological and pathological blood loss, blood donation, dietary intake of iron, alcohol, hepatitis C and B, obesity, and the use of dietary supplements (iron and vitamin C). Additional mechanisms associated with HFE gene mutation, such as exacerbation of coronary artery disease, direct causation of dilatative cardiomyopathy, or autoimmune processes, have been discussed.
2
Our case demonstrates the complexity of storage disease diagnosis. The clinical syndromes, complicating the main underlying disease, were determined first, without a recognition of particular aetiology of those. However, a combination of clinical manifestations such as chronic fatigue, lethargy, bronze skin, arthritis, cardiomyopathy, diabetes, and cirrhosis should serve as red flags and lead the scrupulous clinician to the suspicion of iron metabolism disorder (Figure 3) .
Cardiac magnetic resonance with measurement of T2* relaxation time is superior to other diagnostic modalities since not only it allows not only to detect but also to quantify myocardial iron overload. 3 The time constant of decay for relaxation time is inversely proportional to the iron content in the tissue: the higher iron content, the shorter T2*. 4 Diastolic cardiac dysfunction secondary to restrictive physiology may be seen early in the disease, while later dilated cardiomyopathy with LV systolic dysfunction may prevail. Newer modalities such as strain imaging hold promise for earlier detection of cardiac involvement. 5, 6 The diagnostic pathway of our patient is presented in Figure 3 . The combination of magnetic resonance imaging of the heart and liver with the result of genetic testing made a liver or cardiac biopsy unnecessary in this case. 7 The management of iron overload with proper iron chelation therapy and therapeutic phlebotomy guided by CMR T2* relaxometry is the key to haemochromatosis treatment, in addition to other diseases-specific modalities and the conventional HF therapy. 8 Close family members of newly diagnosed patients should be screened for an asymptomatic disease. The treatment decisions were influenced by the limited availability and high cost of chelates in Lithuanian market, with deferiprone accessible only. According to the recommendations, [7] [8] [9] phlebotomies are the treatment of choice in non-anaemic patients, with ferritin level >300 mg/L in men; with haemoglobin and haematocrit levels ranging within 120-130 g/L and 0.38-0.41, respectively, phlebotomy was considered as adequate therapy for our patient, giving a positive response. A marked and clinically significant improvement in LVEF was observed in our case; first of all, it may be attributed to the wellknown effect of anti-remodelling therapy of angiotensin-converting enzymes inhibitor, beta-blocker, and mineralocorticoid receptor antagonist, 10 which was newly started during index hospitalization.
Second, partially effect may be associated with a reduction of iron accumulation, which similarly was reported in haemochromatosis cases by other authors. 11, 12 The difference between follow-up and baseline values of LVEF far exceeds the established variability of this parameter. 13 However, the increase of T2* relaxation times in the heart and liver was relatively low compared with other cases reported in the literature 14, 15 ; it may be explained by the lack of chelating therapy for our patient.
Conclusion
Hereditary or Type I haemochromatosis is an important specific cause of HF, usually manifesting in the 4-5th decade. Timely detection of this systemic disorder could prevent multiple organ damage. Physicians should remember the red flags of this disease: combination of bronze skin, diabetes, cirrhosis, arthritis, and cardiomyopathy. Biochemical indicators and T2* relaxation time on CMR provide not only diagnostic value but also in addition help to quantify the treatment effect. Specific chelation, regular phlebotomies, and standard Figure 3 The scheme of diagnostic workup and the red flags of haemochromatosis. 
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